



UCB Pharma announces partnership with Dynavax to develop and market products for the treatment of allergies

Brussels, 6 February 2004 - UCB announced today that its pharmaceutical sector, UCB Pharma, has entered into a research and development collaboration and licensing agreement with Dynavax Technologies Corporation for the purpose of drug development and marketing of prophylactic treatments for severe allergies. Following this agreement UCB Pharma will develop and market Dynavax's novel allergy treatments globally. UCB Pharma has licensed the technology, know-how, pre-clinical and clinical data related to Dynavax's phase IIb ragweed and pre-clinical grass allergy therapies and has also been granted an option to license Dynavax's pre-clinical peanut allergy programme.

Worldwide millions of patients suffer from allergies. Dynavax's novel approach, based on the subcutaneous administration of immunostimulatory sequences conjugated with specific allergens in a short term treatment regimen, addresses the cause of severe allergies and has the potential to make prophylactic allergy treatment more effective and convenient. Through the agreement UCB Pharma expects to expand the portfolio of allergy treatments it provides to physicians and patients worldwide.

Under the agreement Dynavax will receive an upfront fee and additional payments based on the achievement of defined clinical and regulatory objectives. UCB Pharma will fund the continued research and development programme of the licensed treatments for its full term. If any of the licensed programmes are approved for marketing Dynavax will receive royalties. Under specific circumstances UCB Pharma has agreed to Dynavax retaining an option to co-promote any approved product in the United States.

Tom Beck, Director of Research and Development at UCB Pharma, commented: "Allergies are widespread and debilitating. Prophylactic treatment is of paramount importance to the millions of people who suffer daily from an abnormal immune response. Combining the innovative expertise of Dynavax with the development and marketing experience of UCB Pharma will accelerate both our efforts to make effective new treatments available to patients faster. UCB Pharma particularly welcomes the agreement with Dynavax as we share many common goals."

ends

About UCB Pharma

UCB Pharma is one of Europe's leading pharmaceutical companies. It is active in all the world's major markets, specialising in the fields of allergy and respiratory diseases and in treatments for disorders of the central nervous system. Among products developed by UCB Pharma are XYZAL® (levocetirizine) a novel antihistamine, ZYRTEC® (cetirizine) the world's most widely used second generation antihistamine, and KEPPRA® (levetiracetam) a novel adjunctive therapy for the treatment of partial onset seizures associated with epilepsy. With

over 6500 employees and operating in over 100 countries, UCB Pharma's global headquarters are in Brussels, Belgium. In 2003 it achieved a consolidated turnover of €1463 million.

About Dynavax

Dynavax Technologies discovers, develops and intends to commercialise innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programmes are based on immunostimulatory sequences (ISS), which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Enquiries

UCB Pharma

Media Enquiries:

Margaret Morgan
Head of Pharma Communication
UCB Pharma
Tel: ++ 32 (0)2 559.93.42
Cell: ++ 32 (0) 499 56.57.80
Email: margaret.morgan@ucb-group.com

Investor Enquiries

Arnaud Denis
Investor Relations Officer
UCB Group
Tel: ++ 32 (0)2 559.92.64
Cell: ++ 32 (0) 478.99.82.37.
Email: arnaud.denis@ucb-group.com